HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 425 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,821 | +1290.1% | 47,664 | +1207.7% | 0.02% | +2000.0% |
| Q2 2023 | $131 | -92.5% | 3,645 | -92.0% | 0.00% | -95.0% |
| Q1 2023 | $1,750 | -38.4% | 45,830 | -8.2% | 0.02% | -42.9% |
| Q4 2022 | $2,841 | -99.9% | 49,932 | -24.6% | 0.04% | +9.4% |
| Q3 2022 | $2,619,000 | +102.2% | 66,233 | +125.1% | 0.03% | +128.6% |
| Q2 2022 | $1,295,000 | -51.2% | 29,424 | -55.7% | 0.01% | -26.3% |
| Q1 2022 | $2,651,000 | -28.4% | 66,462 | -27.8% | 0.02% | -5.0% |
| Q4 2021 | $3,702,000 | +70.4% | 92,061 | +72.3% | 0.02% | +100.0% |
| Q3 2021 | $2,173,000 | +75.1% | 53,416 | +95.4% | 0.01% | +66.7% |
| Q2 2021 | $1,241,000 | -2.5% | 27,338 | -10.4% | 0.01% | -14.3% |
| Q1 2021 | $1,273,000 | +43.5% | 30,525 | +47.0% | 0.01% | +40.0% |
| Q4 2020 | $887,000 | +46.6% | 20,768 | -9.7% | 0.01% | +25.0% |
| Q3 2020 | $605,000 | -71.6% | 23,009 | -71.0% | 0.00% | -77.8% |
| Q2 2020 | $2,130,000 | +26.0% | 79,461 | -15.4% | 0.02% | +12.5% |
| Q1 2020 | $1,690,000 | +349.5% | 93,920 | +343.4% | 0.02% | +433.3% |
| Q4 2019 | $376,000 | +130.7% | 21,183 | +102.1% | 0.00% | +200.0% |
| Q3 2019 | $163,000 | +11.6% | 10,482 | +23.4% | 0.00% | 0.0% |
| Q2 2019 | $146,000 | -77.8% | 8,496 | -79.2% | 0.00% | -83.3% |
| Q1 2019 | $657,000 | +194.6% | 40,781 | +167.4% | 0.01% | +200.0% |
| Q4 2018 | $223,000 | +64.0% | 15,249 | +89.1% | 0.00% | +100.0% |
| Q2 2018 | $136,000 | -13.9% | 8,066 | +0.2% | 0.00% | 0.0% |
| Q1 2018 | $158,000 | -67.6% | 8,050 | -71.3% | 0.00% | -75.0% |
| Q3 2017 | $488,000 | -6.3% | 28,081 | -30.9% | 0.00% | -20.0% |
| Q2 2017 | $521,000 | +52.3% | 40,617 | +54.0% | 0.01% | +66.7% |
| Q1 2017 | $342,000 | -50.8% | 26,379 | -62.5% | 0.00% | -50.0% |
| Q4 2016 | $695,000 | +100.9% | 70,344 | +145.6% | 0.01% | +50.0% |
| Q3 2016 | $346,000 | +68.0% | 28,642 | +31.8% | 0.00% | +300.0% |
| Q1 2016 | $206,000 | -28.2% | 21,724 | +1.7% | 0.00% | -50.0% |
| Q3 2015 | $287,000 | +81.6% | 21,360 | +204.4% | 0.00% | +100.0% |
| Q2 2015 | $158,000 | -38.5% | 7,017 | -60.9% | 0.00% | -50.0% |
| Q1 2015 | $257,000 | +53.9% | 17,966 | +4.0% | 0.00% | +100.0% |
| Q4 2014 | $167,000 | -12.6% | 17,276 | +15.0% | 0.00% | 0.0% |
| Q1 2014 | $191,000 | -21.1% | 15,028 | -31.5% | 0.00% | 0.0% |
| Q3 2013 | $242,000 | – | 21,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |